Research Articles - Retinitis Pigmentosa
A Foundation-funded investigative team led by Ruifang Sui, M.D., Ph.D., of Peking Union Medical College Hospital, has completed the first comprehensive genetic screening of a group of Chinese people with autosomal recessive retinitis pigmentosa (arRP). Results of the
The Argus II® Retinal Prosthesis System, which restores some useful vision to people blind from advanced retinitis pigmentosa, will be offered later this year at 12 clinical centers throughout the United States.
The Argus II retinal prosthesis, a device that can restore some vision to people who are blind from advanced retinitis pigmentosa (RP), has received U.S. market approval from theFood and Drug Administration (FDA). Developed by Second Sight Medical Products, the device will be available later this year in approximately 10 clinical centers across the country. In 2011, the Argus II received marketing approval in Europe. Also known as a “bionic retina,” it is currently the world’s only retinal
The Alpha IMS, a subretinal implant developed by Retina Implant AG of Reutlingen, Germany, has been granted European marketing approval. The device received a CE Mark, a regulatory designation for meeting European safety and reliability standards. Also known as an artificial or bionic retina, the Alpha IMS has
An artificial retina developed by Retina Implant AG of Reutlingen, Germany, has restored meaningful vision to most of the nine blind people — eight with retinitis pigmentosa, one with cone-rod dystrophy — enrolled in a clinical trial. Five of the participants recognized objects such as door knobs, telephones and facial features. One person was able to read store and restaurant signs, and another was able to observe the movements of a wild goose.
Interim results of the clinical trial were published online in
The Foundation is bolstering its commitment to restoring vision for people with the most advanced retinal diseases by investing $800,000 in the development of two emerging optogenetic therapies at the University of California, Berkeley. The funding is in addition to nearly $1.5 million that the Foundation is already providing to the Institut de la Vision in Paris for advancement of itsoptogenetics treatment. The overarching goal of all three projects is to prepare the therapies for clinical trials.
The Argus II® Retinal Prosthesis System, the first and only artificial retina to be approved by the U.S. Food and Drug Administration, will be at least partially covered under Medicare. Payment for both the system and implantation surgery will be provided. Further details of the implementation of Medicare payments — including the amounts of reimbursement and out-of-pocket costs — are forthcoming. People who are considered disabled because of vision loss may qualify for Medicare.
Researchers from the University of California, Davis (UC Davis), have launched a Phase I clinical trial of CD34+ bone marrow stem cells (BMSC) for people with retinal conditions that cause vision loss from ischemia, or loss of blood flow, and cell degeneration. Led by Dr. Susanna Park, the investigative
The development program for a new drug with the potential to treat a common form of autosomal dominant retinitis pigmentosa (adRP) has received a boost with Shire’s acquisition of BIKAM Pharmaceuticals, the original developer of the experimental treatment.
The Foundation Fighting Blindness Clinical Research Institute (FFB CRI) has completed patient enrollment for its Phase II clinical trial for valproic acid, a therapy which has shown some suggestion of slowing loss of visual function in people with autosomal dominant retinitis pigmentosa (adRP). Valproic acid was previously approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizure disorders. The 90-participant study of valproic acid for people with confirmed adRP was